DNA微陣列市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、應用、最終用途、地區和競爭格局分類，2021-2031年）

全球DNA微陣列市場預計將從2025年的24.3億美元成長到2031年的40.6億美元，複合年成長率為8.93%。

這些分析設備能夠將微小的DNA片段固定在固體相基質上，在量化基因表現水平和同時對不同基因組區域進行基因分型方面發揮著至關重要的作用。市場成長的主要驅動力是癌症和遺傳疾病發生率的上升，這導致個人化醫療和藥物研發領域對高通量診斷儀器的需求激增。生命科學領域的大規模資本注入進一步推動了這一成長。根據美國藥品研究與製造商協會（PhRMA）預測，其成員公司將在2024年投入約1,010億美元用於研發，為基因組技術的應用奠定了堅實的資金基礎。

儘管微陣列技術取得了這些進展，但它仍面臨著一個重大挑戰：來自次世代定序（NGS）的激烈競爭。由於NGS平台具有更高的靈敏度，並且能夠識別基於晶片的方法難以檢測到的新型基因變異，研究人員正逐漸將選擇轉向定序解決方案。這種技術轉變對微陣列技術的持續應用構成了重大威脅，尤其是在需要全面基因組發現能力的高階研究領域。

市場促進因素

遺傳性疾病和癌症的日益普遍是全球DNA微陣列市場的主要驅動力，因為這些工具對於高通量基因表現分析和拷貝數變異分析至關重要。臨床醫生高度依賴微陣列來識別與複雜病理相關的生物標記物，而癌症疾病負擔的不斷加重進一步凸顯了這種需求。根據美國癌症協會於2025年1月發布的《2025年癌症事實與數據》報告，預計僅在美國就將新增2,041,910例癌症病例。這一成長趨勢要求使用可靠的診斷平台，並確保即使在其他定序方法興起的情況下，人們仍將繼續依賴基於微陣列的技術。

此外，微陣列技術在藥物基因組學和藥物發現領域的應用日益廣泛，簡化了毒性篩檢和目標分子識別流程，也顯著推動了市場成長。製藥公司正利用這些平台追蹤基因表現對潛在療法的反應變化，加速個人化醫療的研發。這一蓬勃發展的產業也體現在主要企業的財務表現中。安捷倫科技公司於2025年2月發布的「2025會計年度第一季財務報告」預測，生命科學和診斷市場領域的銷售額將達到6.47億美元。該產業的龐大規模進一步凸顯了這一投資趨勢。據Illumina公司稱，2025年營收將達43億美元，高於2024年全年營收，顯示支持微陣列市場的基因組技術將持續獲得資金流入。

市場挑戰

全球DNA微陣列市場成長的主要障礙是來自次世代定序（NGS）技術的激烈競爭。儘管微陣列在基因表現檢測方面有著悠久的成功歷史，但NGS平台具有顯著的技術優勢，包括更高的靈敏度以及發現基於微陣列方法難以檢測到的新型基因突變的能力。這種功能能夠實現更全面的基因組分析，並在複雜的診斷應用和高階研究中變得日益重要。因此，隨著研究人員將資料深度置於傳統微陣列的成本優勢之上，實驗室對定序的偏好發生了顯著轉變。

大量資金湧入製藥創新領域，進一步推動了定序的普及，而精準性在製藥創新領域至關重要。根據歐洲製藥工業協會聯合會（EFPIA）預測，到2024年，以研發為基礎的製藥業將在歐洲的研發領域投入約550億歐元。如此龐大的投資凸顯了市場格局的趨勢：優先採用最先進的診斷工具以最佳化研究成果。隨著越來越多的資金投入到能夠提供更深入基因組資訊以用於個人化醫療和藥物研發的技術中，DNA微陣列的市場佔有率和長期發展正受到新一代定序（NGS）日益成長的主導地位的直接威脅。

市場趨勢

農業和環境基因組學應用範圍的不斷擴大，正使其市場超越傳統的人類診斷領域。研究人員擴大利用高通量晶片基因分型技術，在畜牧改良和作物育種計劃中進行標記輔助選擇。這一轉變的驅動力源於永續糧食生產的迫切需求以及快速識別農業環境中病原體的需求，而微陣列技術為篩檢多樣化的基因組提供了一種經濟高效的解決方案。這些創新正得到資金的大力支持。根據美國國家食品與農業研究所（NIFA）於2024年7月發布的《NIFA最新動態》，該研究所宣布將投資800萬美元，透過16項津貼支持農業植物生理學研究，直接促進該領域先進基因組工具的應用。

同時，人工智慧（AI）與生物資訊學流程的融合正在改變複雜微陣列資料的解讀方式。隨著陣列密度的增加，產生的數據量往往超出標準統計方法的承受能力，因此需要藉助人工智慧演算法進行自動化影像分析、精確探針設計和準確的基因表現分析。這種融合顯著提高了基因分型的速度，並加速了廣泛的基因組數據與表現型特徵之間的相關性分析，使陣列技術在複雜研究中更具實用性。計算醫學領域估值的不斷攀升也印證了這種融合的商業性潛力。在2025年1月舉行的摩根大通醫療保健大會上，英偉達預測其醫療保健和生命科學部門到2025年將創造10億美元的經常性收入，凸顯了推動人工智慧驅動的基因組分析的大量資金流入。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球DNA微陣列市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（互補DNA微陣列、寡核苷酸DNA微陣列、其他）
  • 依應用領域（基因表現分析、基因型分析等）
  • 按最終用戶（製藥和生物技術公司、診斷中心、醫院和診所、學術研究機構等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美DNA微陣列市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲DNA微陣列市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區DNA微陣列市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東與非洲DNA微陣列市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲DNA微陣列市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球DNA微陣列市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific, Inc.
• QIAGEN NV
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Merck KGaA
• bioMerieux SA
• PerkinElmer, Inc.
• Applied Micro Arrays Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global DNA Microarray Market is anticipated to expand from USD 2.43 Billion in 2025 to USD 4.06 Billion by 2031, reflecting a CAGR of 8.93%. These analytical devices, characterized by microscopic DNA spots affixed to a solid matrix, are essential for quantifying gene expression levels or genotyping various genomic regions simultaneously. The market's upward trajectory is largely fueled by the increasing incidence of cancer and genetic disorders, which creates a critical need for high-throughput diagnostic instruments in personalized medicine and drug discovery. This growth is bolstered by substantial capital infusion into life sciences innovation; according to the Pharmaceutical Research and Manufacturers of America, member companies invested nearly $101 billion in research and development in 2024, fostering a robust financial landscape for the implementation of genomic technologies.

Despite these advancements, the market encounters a formidable obstacle in the form of intense competition from Next-Generation Sequencing (NGS). NGS platforms provide enhanced sensitivity and the capacity to identify novel genetic variants that are often undetectable by array-based techniques, leading to a gradual migration of researcher preference toward sequencing solutions. This technological shift represents a significant threat to the sustained adoption of microarrays, especially within high-end research segments that demand exhaustive genomic discovery capabilities.

Market Driver

The escalating prevalence of genetic disorders and cancer serves as a primary catalyst for the Global DNA Microarray Market, rendering these tools essential for high-throughput gene expression profiling and the analysis of copy number variations. Clinicians depend heavily on microarrays to isolate biomarkers linked to complex pathologies, a need highlighted by the rising burden of oncological diseases. According to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025' report, it was projected that 2,041,910 new cancer cases would be diagnosed in the United States alone. This growing incidence mandates the use of reliable diagnostic platforms, ensuring continued reliance on array-based technologies even amidst the rise of alternative sequencing methods.

Moreover, market growth is significantly strengthened by the broadening utilization of microarrays in pharmacogenomics and drug discovery, where they streamline toxicity screening and target identification. Pharmaceutical entities employ these platforms to track gene expression shifts in response to potential therapeutics, thereby expediting the creation of personalized medicines. The vitality of this sector is reflected in the financial results of major industry participants; according to Agilent Technologies, February 2025, in the 'First-Quarter Fiscal Year 2025 Financial Results', the Life Sciences and Diagnostics Markets Group achieved revenue of $647 million. This investment trend is further emphasized by the industry's sheer scale; according to Illumina, in 2025, the company reported full-year 2024 revenue of $4.3 billion, demonstrating the persistent capital flow into genomic technologies that supports the microarray market.

Market Challenge

A major impediment to the Global DNA Microarray Market is the fierce competition presented by Next-Generation Sequencing (NGS) technologies. Although microarrays have a long-standing reputation for measuring gene expression, NGS platforms offer distinct technical benefits, including superior sensitivity and the capacity to uncover novel genetic variants that array-based approaches frequently fail to detect. This functionality facilitates a more exhaustive genomic analysis, which is becoming increasingly vital for complex diagnostic applications and high-end research. Consequently, there is a noticeable shift in laboratory preference toward sequencing, as researchers prioritize data depth over the cost advantages historically linked to microarrays.

This transition toward sequencing is further accelerated by significant financial resources dedicated to pharmaceutical innovation, a field where precision is essential. According to the European Federation of Pharmaceutical Industries and Associations, in 2024, the research-based pharmaceutical industry invested an estimated €55,000 million in R&D in Europe. Such massive investment highlights a market landscape that privileges the adoption of the most sophisticated diagnostic tools available to optimize research results. As funding increasingly targets technologies capable of providing deeper genomic insights for personalized medicine and drug discovery, the market share and long-term expansion of DNA microarrays are directly challenged by the growing dominance of NGS.

Market Trends

The Expansion of Applications in Agricultural and Environmental Genomics is extending the market's reach beyond its conventional focus on human diagnostics. Increasingly, researchers are deploying high-throughput array-based genotyping for marker-assisted selection within livestock improvement and crop breeding initiatives. This shift is motivated by the urgent requirement for sustainable food production and the swift identification of pathogens in agricultural environments, where microarrays provide a cost-efficient solution for screening varied genomes. Financial backing is actively accelerating these innovations; according to the National Institute of Food and Agriculture, July 2024, in the 'NIFA Update', the agency announced an investment of $8 million across 16 awards to support research in the physiology of agricultural plants, directly encouraging the use of advanced genomic tools in this sector.

Concurrently, the Integration of Artificial Intelligence in Bioinformatics Pipelines is transforming the interpretation of complex microarray data. As the density of arrays grows, the massive volume of data produced often exceeds the limits of standard statistical techniques, requiring AI algorithms for automated image analysis, precise probe design, and accurate gene expression profiling. This incorporation drastically improves the speed of genotype calling and hastens the correlation of extensive genomic data with phenotypic traits, thereby making array technology more viable for intricate studies. The commercial strength of this convergence is illustrated by the rising valuation of computational healthcare; according to NVIDIA, January 2025, in a presentation at the 'J.P. Morgan Healthcare Conference', the company projected that its healthcare and life sciences vertical would generate $1 billion in recurring revenue by 2025, underscoring the substantial capital inflow driving AI-powered genomic analysis.

Key Market Players

• Thermo Fisher Scientific, Inc.
• QIAGEN NV
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Merck KGaA
• bioMerieux S.A.
• PerkinElmer, Inc.
• Applied Micro Arrays Ltd.

Report Scope

In this report, the Global DNA Microarray Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Microarray Market, By Type

• Complementary DNA Microarrays
• Oligonucleotide DNA Microarrays
• Others

DNA Microarray Market, By Application

• Gene Expression Analysis
• Genotyping
• Others

DNA Microarray Market, By End Use

• Pharmaceutical and Biotechnology Companies
• Diagnostic Centers
• Hospitals and Clinics
• Academic and Research Institute
• Others

DNA Microarray Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Microarray Market.

Available Customizations:

Global DNA Microarray Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global DNA Microarray Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Complementary DNA Microarrays, Oligonucleotide DNA Microarrays, Others)
  • 5.2.2. By Application (Gene Expression Analysis, Genotyping, Others)
  • 5.2.3. By End Use (Pharmaceutical and Biotechnology Companies, Diagnostic Centers, Hospitals and Clinics, Academic and Research Institute, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America DNA Microarray Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States DNA Microarray Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada DNA Microarray Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico DNA Microarray Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End Use

7. Europe DNA Microarray Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany DNA Microarray Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End Use
  • 7.3.2. France DNA Microarray Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom DNA Microarray Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy DNA Microarray Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain DNA Microarray Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End Use

8. Asia Pacific DNA Microarray Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China DNA Microarray Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End Use
  • 8.3.2. India DNA Microarray Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan DNA Microarray Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea DNA Microarray Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia DNA Microarray Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End Use

9. Middle East & Africa DNA Microarray Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia DNA Microarray Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End Use
  • 9.3.2. UAE DNA Microarray Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End Use
  • 9.3.3. South Africa DNA Microarray Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End Use

10. South America DNA Microarray Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil DNA Microarray Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End Use
  • 10.3.2. Colombia DNA Microarray Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End Use
  • 10.3.3. Argentina DNA Microarray Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global DNA Microarray Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. QIAGEN NV
• 15.3. Illumina, Inc.
• 15.4. F. Hoffmann-La Roche Ltd.
• 15.5. Agilent Technologies, Inc.
• 15.6. Merck KGaA
• 15.7. bioMerieux S.A.
• 15.8. PerkinElmer, Inc.
• 15.9. Applied Micro Arrays Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer